New drug duo aims to outsmart advanced kidney cancer
NCT ID NCT05928806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing a new combination of two immunotherapy drugs, botensilimab and balstilimab, against the standard combination of ipilimumab and nivolumab for people with advanced kidney cancer that has spread. The study plans to enroll 120 patients who have not had prior treatment. The goal is to see if the new combo shrinks tumors more effectively and for a longer time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new, possibly more effective immunotherapy option for people with advanced kidney cancer.
What could go wrong
This is a Phase 2 trial, so it's still early. The new combo may not work better than the standard treatment, and it could have serious side effects like immune system attacks on healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Cornell University
Ithaca, New York, 14850, United States
-
Dana-Farber - Partners Cancer Care, Inc
Boston, Massachusetts, 02215, United States
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
-
Yale University, Yale Cancer Center
New Haven, Connecticut, 06520, United States